
Elicera Therapeutics Q4 - Eventful 2025 ahead

Redeye returns following Elicera's Q4 report and recent news in the company. We largely reiterate our stance, but make some additional changes to our valuation, leading to a slight increase in our base case.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Elicera Therapeutics Q4 - Eventful 2025 ahead](#)